Principal Investigators

    M.Ankarcrona, J.Prehn, P.Pizzo, D.Bano, D.Park



    Contact information of lead PI



    Title of project or programme

    CeBioND: Cellular Bioenergetics in Neurodegenerative Diseases: A system based pathway and target analysis

    Source of funding information

    JPND-Cross Disease

    Total sum awarded (Euro)

    € 1,475,261

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias|Parkinson's disease & PD-related disorders|Huntington's disease


    Research Abstract

    Mitochondria are parts of every cell that provide energy to enable cells to perform their day-to-day duties. However mitochondria can also kill cells by producing damaging molecules or by initiating a cell suicide program. These processes are believed to play a key role in the degenerative changes associated with Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). CeBioND aims to understand if impairments in mitochondrial function are sufficient to trigger these neurodegenerative disorders, or if they represent an additional risk factor (‘second hit’ hypothesis) for developing the disease. It is also im- portant to test whether mitochondria and different ways to ‘boost’ the cell’s energy represent ‘true’ therapeutic targets.CeBioND assembles a team of international experts with a track record in analysis of mitochondrial functions and energetics research. To determine the contribution of mitochondria and cell bioenergetics to disease progression in AD, PD and HD we will use two complementary approaches: 1) Analysis of common disease mechanisms focusing on alterations in mitochondrial functions and in the signalling pathways regulating bioenergetics. 2) High-throughput screen to identify drugs enhancing mitochondrial functions and demonstrating neuroprotection.The CeBioND consortium will deliver much required insights into the contribution of mitochondria dysfunctions and bioenergetics to neurodegeneration in AD, PD and HD and will deliver novel therapeutic strategies. There are no disease modifying drugs currently on the market and therefore the CeBioND initiative is of highest importance as part of the work to understand the disease mechanisms and to develop efficient treatments for these devastating diseases

    Lay Summary

    Further information available at:

Types: Investments > €500k, JPND Projects
Member States: Canada, Germany, Ireland, Italy, JPND, Sweden
Diseases: Alzheimer's disease & other dementias, Huntington's disease, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF